110 related articles for article (PubMed ID: 6368760)
1. High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study.
Wolff SN; Johnson DH; Hainsworth JD; Greco FA
J Clin Oncol; 1984 Apr; 2(4):271-4. PubMed ID: 6368760
[TBL] [Abstract][Full Text] [Related]
2. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.
Wolff SN; Fer MF; McKay CM; Hande KR; Hainsworth JD; Greco FA
J Clin Oncol; 1983 Nov; 1(11):701-5. PubMed ID: 6366131
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy of refractory germ cell cancer with Etoposide.
Lederman GS; Garnick MB; Canellos GP; Richie JP
J Clin Oncol; 1983 Nov; 1(11):706-9. PubMed ID: 6321675
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors.
Mulder PO; de Vries EG; Koops HS; Splinter T; Maas A; van der Geest S; Mulder NH; Sleijfer DT
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):675-9. PubMed ID: 2838293
[TBL] [Abstract][Full Text] [Related]
5. VP-16 in combinations for first-line treatment of malignant germ-cell tumors and gestational choriocarcinoma.
Newlands ES
Semin Oncol; 1985 Mar; 12(1 Suppl 2):37-41. PubMed ID: 2579442
[TBL] [Abstract][Full Text] [Related]
6. [VM-26 and VP-16 salvage therapy for refractory germinal testicular cancers].
Miki T; Tomooka Y; Yoshimura K; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
Nihon Hinyokika Gakkai Zasshi; 1989 Nov; 80(11):1609-16. PubMed ID: 2593435
[TBL] [Abstract][Full Text] [Related]
7. Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors.
Bosl GJ; Yagoda A; Golbey RB; Whitmore W; Herr H; Sogani P; Morse M; Vogelzang N; MacDonald G
Am J Med; 1985 Mar; 78(3):423-8. PubMed ID: 2983547
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of high dose VP 16-213 as single agent or in combination with cyclophosphamide and autologous bone marrow transplantation (ABMT).
Mulder NH; Meinesz AF; Sleijfer DT; Postmus PE; De Vries EG; Van der Geest S; Orie JL; Vriesendorp R
Neth J Med; 1984; 27(10):389-92. PubMed ID: 6096742
[No Abstract] [Full Text] [Related]
10. Etoposide-induced hepatic injury: a potential complication of high-dose therapy.
Johnson DH; Greco FA; Wolff SN
Cancer Treat Rep; 1983 Nov; 67(11):1023-4. PubMed ID: 6315228
[TBL] [Abstract][Full Text] [Related]
11. cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung.
Sierocki JS; Hilaris BS; Hopfan S; Martini N; Barton D; Golbey RB; Wittes RE
Cancer Treat Rep; 1979; 63(9-10):1593-7. PubMed ID: 227598
[TBL] [Abstract][Full Text] [Related]
12. Chronic daily administration of oral etoposide--a phase I trial.
Hainsworth JD; Johnson DH; Frazier SR; Greco FA
J Clin Oncol; 1989 Mar; 7(3):396-401. PubMed ID: 2918334
[TBL] [Abstract][Full Text] [Related]
13. High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors.
Broun ER; Nichols CR; Tricot G; Loehrer PJ; Williams SD; Einhorn LH
Bone Marrow Transplant; 1991 Jan; 7(1):53-6. PubMed ID: 1646050
[TBL] [Abstract][Full Text] [Related]
14. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
Zander AR; Vellekoop L; Spitzer G; Verma DS; Litam J; McCredie KB; Keating M; Hester JP; Dicke KA
Cancer Treat Rep; 1981; 65(5-6):377-81. PubMed ID: 7016323
[TBL] [Abstract][Full Text] [Related]
15. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.
Santana VM; Schell MJ; Williams R; Bowman LC; Thompson EI; Brenner MK; Mirro J
Bone Marrow Transplant; 1992 Nov; 10(5):457-62. PubMed ID: 1464010
[TBL] [Abstract][Full Text] [Related]
16. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer.
Loehrer PJ; Einhorn LH; Williams SD
J Clin Oncol; 1986 Apr; 4(4):528-36. PubMed ID: 3633952
[TBL] [Abstract][Full Text] [Related]
17. High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia.
Van Echo DA; Wiernik PH; Aisner J
Cancer Clin Trials; 1980; 3(4):325-8. PubMed ID: 6933027
[TBL] [Abstract][Full Text] [Related]
18. [A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].
Konno K; Nagahama F; Nakai Y; Nakabayashi T; Hiraga Y; Takebe K; Tamura M; Oizumi K; Sato M; Ito T
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):931-7. PubMed ID: 3008671
[TBL] [Abstract][Full Text] [Related]
19. High-dose etoposide for refractory malignancies: a phase I study.
Postmus PE; Mulder NH; Sleijfer DT; Meinesz AF; Vriesendorp R; de Vries EG
Cancer Treat Rep; 1984 Dec; 68(12):1471-4. PubMed ID: 6509453
[TBL] [Abstract][Full Text] [Related]
20. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.
Nichols CR; Tricot G; Williams SD; van Besien K; Loehrer PJ; Roth BJ; Akard L; Hoffman R; Goulet R; Wolff SN
J Clin Oncol; 1989 Jul; 7(7):932-9. PubMed ID: 2544687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
